Learn about Laboratory Considerations when Developing Multiple Myeloma Trials


30th June, 2016
Time: 11:00 - 12:00

Learn about Laboratory Considerations when Developing Multiple Myeloma Trials

Location: Webinar
Timezone: (GMT -5:00) Eastern Time (US & Canada), Bogota, Lima

Join ICON’s experts Dr. Marc Golightly, PhD and Domenica Gandini as they speak about considerations when developing Multiple Myeloma trials.  With the growing number of therapeutics being developed for Multiple Myeloma, the need for laboratory expertise in Multiple Myeloma clinical trials is paramount to proper evaluation/assessment of patient responses. A knowledge of the pitfalls, how to avoid them, and newer diagnostic testing will all contribute to the success of the study design and analysis of responses. 

Key Insights that will be covered:

  • Basic review of Multiple Myeloma
  • Importance of an experienced  dedicated group of myeloma laboratory technologists and multi-level review of data
  • Centralization of laboratory services and minimizing variation 
  • Understanding and minimizing the pitfalls in laboratory testing of Myeloma patients
  • New technologies available for improving the assessment monoclonal antibody levels

Key Insights: Senior professionals from biopharmaceutical companies working within oncology clinical research.

Featured Speakers

Dr. Marc Golightly, PhD

Dr. Marc Golightly is a Professor of Pathology at Stony Brook University and is the director of the Medical Center’s Clinical Immunology Laboratory, Clinical Flow Cytometry Laboratory, and the University’s Research Flow Cytometry Core Facility. He graduated from UCLA with a Ph.D. in Microbiology and Immunology. Subsequently, he did a post doctorate at UCLA in Tumor Immunology, followed by a three year post doctorate/Fellowship in Clinical Immunology at Duke University.
Since then, he rose through the ranks from assistant professor to full professor at Stony Brook University in New York and has been extensively involved with laboratory diagnosis of multiple myeloma for over 30 years. In addition, he has been a consultant at Icon Central Laboratories in Farmingdale, NY for Myeloma clinical trials and Flow cytometry since 2000. He has over 115 publications in peer reviewed journals and invited chapters in books and has been invited to speak at numerous national and international meetings.

Dr. Domenica Gandini, MD, PhD

Dr. Domenica Gandini is a Medical Director, based in ICON’s Southampton, UK office. Domenica acquired her Medical degree from the University of Ferrara in Italy before gaining subsequent Completion of Specialization, Haematology credentials (Italian and GMC registry) and a Ph.D. in Experimental Haematology from the Universities of Modena and Ferrara. After her Clinical Training, Domenica worked as a Post-Doctoral fellow in Institutions both in Europe and US such as the Haematology Department of the University of Ferrara, the Haematology Department at the Royal Postgraduate Medical School in London, UK, the Human genetics Department at the Memorial Sloan Kettering Cancer Centre in New York, and the Haematology Department of the University College London, UK and attended the Lymphoma Clinic at Bart’s and the London Hospital, London.
Domenica’ s research and interest mainly focused on Molecular mechanisms of both Myeloid and Lymphoid Haematological Malignancies.  Domenica joined ICON in 2008 and since then has been monitoring mainly clinical trials with Haematology/ Oncology Indications including, among others Multiple Myeloma, AML, Chronic Lymphocytic Leukaemia and Lymphomas. 

Target Audience

This program is intended for senior professionals from biopharmaceutical companies working within oncology clinical research.